Ameriprise
IMCR icon

Ameriprise’s Immunocore IMCR Stock Holding History

Ameriprise’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-135,207
Closed -$4.69M – 4144
2025
Q4 		$4.69M Buy
+135,207
New +$4.77M ﹤0.01% 2472
2024
Q2 		– Sell
-24,866
Closed -$1.62M – 3905
2024
Q1 		$1.62M Buy
24,866
+1,224
+5% +$84K ﹤0.01% 2974
2023
Q4 		$1.62M Sell
23,642
-100
-0.4% -$5.2K ﹤0.01% 2979
2023
Q3 		$1.23M Sell
23,742
-73,403
-76% -$4.34M ﹤0.01% 3048
2023
Q2 		$5.82M Buy
97,145
+1,396
+1% +$79.7K ﹤0.01% 2227
2023
Q1 		$4.73M Buy
95,749
+74,637
+354% +$4.2M ﹤0.01% 2353
2022
Q4 		$1.21M Buy
21,112
+700
+3% +$39.4K ﹤0.01% 3042
2022
Q3 		$959K Buy
+20,412
New +$973K ﹤0.01% 3132

Other funds holding IMCR

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Ameriprise's IMCR Position: Q1 2026 in Review

Ameriprise sold out of Immunocore (IMCR) in Q1 2026, closing a stake of 135,207 shares — an estimated $4.69M sold.

Ameriprise first reported a position in IMCR in Q3 2022 and held it in 8 quarters. The position peaked at $5.82M in Q2 2023. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Ameriprise reported no remaining Immunocore position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 135,207 Immunocore shares in Q1 2026, an estimated $4.69M.
  • Ameriprise first reported a position in Immunocore in Q3 2022 and held it in 8 quarters.
  • Ameriprise's Immunocore position peaked at $5.82M in Q2 2023.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.